Abstract 262P
Background
There are 5,7 male and 3,8 female Non Hodgkin Lymphoma (NHL) patients per 100,000 populations in Indonesia. The expression of pPI3K/pAKT/pMTOR is an important expression in patients with NHL. Cascade signals from these biomarkers lead to translational regulation, cell survival, cytoskeleton organization, and ion transport. Lactate dehydrogenase (LDH) is an important marker in patients with NHL. pPI3K/pAKT/pMTOR increases gene transcription and encourages LDH proliferation.
Methods
An observational study by observing and measuring cancer cell samples from patients. Data collection method is cross sectional in which the independent and dependent variables are examined simultaneously. The expression values of pPI3K, pAKT, and pMTOR are expressed in form of histoscore. There are three range of intensity values which are one means weak, two means medium, and three mean strong, while the four distribution range are one means <20%, two means 20-50%, three means 50-80%, and four means >80%. Therefore the possible range of histoscore is from 1 to 12.
Results
The mean phosphorylated PI3K expression in NHL patients is 5,29 (2,95). The mean phosphorylated AKT expression in NHL patients is 4,71 (2,26). The mean expression of phosphorylated MTOR in NHL patients is 7,62 (1,86). The mean serum LDH level NHL patients is 428,57 (139,63) IU/L.
Conclusions
Correlation between the average expressions of pPI3K with the average level of serum LDH in NHL patients is relatively weak. The correlation between the mean of PAKT expression and the average level of LDH serum in NHL patients is classified as very weak. The correlation between mean pMTOR expression and mean serum LDH levels in NHL patients is very weak.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Andalas University, Padang.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
413P - South Korean real-world treatment patterns in patients with EGFRm NSCLC
Presenter: Jae Cheol Lee
Session: e-Poster Display Session
414P - Incidence and characteristics of lung cancer diagnosed after kidney transplantation at the National Kidney and Transplant Institute
Presenter: Adeline Gonzales
Session: e-Poster Display Session
415P - Real-world fusion landscape of RET gene fusions and its response to cabozantinib in Chinese non-small cell lung cancer (NSCLC) using next generation sequencing
Presenter: Chunwei Xu
Session: e-Poster Display Session
416P - A single institute study evaluating the additional benefit of blood NGS testing over conventional molecular testing in metastatic adenocarcinoma lung
Presenter: Rajashree Ashwath
Session: e-Poster Display Session
417P - Efficacy and safety of lorlatinib in subsequent lines of therapy in ALK and ROS1 positive lung cancer
Presenter: Amit Kumar
Session: e-Poster Display Session
418P - All EGFR mutations are (not) created equal: Focus on uncommon EGFR mutations
Presenter: Ullas Batra
Session: e-Poster Display Session
419P - Surgical treatment of malignant tumours and metastatic lesions of the chest wall
Presenter: Zhanat Pyssanova
Session: e-Poster Display Session
421P - A multicenter, randomized, double-blind, placebo (PBO)-controlled, phase III trial of lenvatinib (LEN) in patients (pts) with radioiodine-refractory differentiated thyroid cancer (RR-DTC) in China
Presenter: Ming Gao
Session: e-Poster Display Session
422P - Response rate and time to progression after first line chemotherapy with cisplatin and adriamycin in patients with metastatic osteosarcoma at presentation
Presenter: Sivasubramaniam Kumaravelu
Session: e-Poster Display Session
423P - Positive lymph node and thicker Breslow are associated with poor prognosis of high-risk resected melanomas
Presenter: Roby Cahyono
Session: e-Poster Display Session